UPPSALA, SWEDEN - LIDDS AB (publ) announced today that a patent application related to NanoZolid for treatment of brain cancers was filed to the European patent office. The patent application relates to a method to treat brain cancer with intratumoral depots providing a controlled drug release at the tumor site.
Advances in treatments of malignant brain tumors have only modestly improved survival rates of patients. LIDDS can with the NanoZolid technology expand its platform to brain cancer by circumventing the blood-brain barrier and to increase the drug distribution within the tumor area.
"It is with excitement that we file a patent in this important area with a large unmet medical need," said Monica Wallter, CEO of LIDDS. "Our favorable preclinical results on the NanoZolid carrier in brain tissue, together with the drug release characteristics that we can obtain with our technology, form the basis for this invention. I am hopeful that this development and potential commercialization will bring new hope to brain cancer patients".
The application describes treatment methods with NanoZolid formulations that are administered transcranially with minimally invasive image guided injection techniques to form intratumoral depots that administer substances to the tumor while minimizing damage on the surrounding healthy brain tissue. The NanoZolid technology can be applied to a large number of relevant active substances.
For more information, please contact:
Monica Wallter, CEO, +46
LIDDS AB) For more information, please visit www.liddspharma.com.
